Pressemitteilungen

Bitte wählen Sie Jahr

Novartis receives European Commission approval for Pluvicto® as the first targeted radioligand therapy for treatment of progressive PSMA–positive metastatic castration-resistant prostate cancer

Dez 13, 2022

Novartis receives positive CHMP opinion for Pluvicto® for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer

Okt 14, 2022

Novartis resumes production and delivery of radioligand therapy medicines ahead of schedule

Jun 30, 2022

Novartis provides update on production of radioligand therapy medicines

Mai 5, 2022

Novartis PluvictoTM approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer

Mrz 23, 2022

FDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC)

Sep 28, 2021

Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021

Sep 17, 2021

Positive survival data for Novartis investigational radioligand therapy 177Lu-PSMA-617 published in The New England Journal of Medicine

Jun 23, 2021

Novartis receives FDA Breakthrough Therapy designation for investigational 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC)

Jun 16, 2021

Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study

Jun 3, 2021

Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera

Jun 3, 2021

Novartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP)

Mrz 30, 2021

Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer

Mrz 23, 2021

Advanced Accelerator Applications to Build Targeted RadioLigand Therapy Production Facility in Indianapolis

Jun 30, 2020

Advanced Accelerator Applications Announces Health Canada Approval of NETSPOT® Diagnostic Imaging Agent Kit to Detect Neuroendocrine Tumours

Apr 7, 2020

Media Contacts

Rachel Levine
Global Head of Communications and Patient Advocacy
rachel.levine@novartis.com
+1-917-375-2935

Veronique Mermet
Global Communications Specialist
info@adacap.com
+33 (0)4 50 99 30 70